1.	Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Phase: Phase IV Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 13 to 15 at first immunization Sponsor: Other Protocol IDs: HPV CSP01, NCT00956553
2.	Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Phase: Phase IV Type: Prevention Status: Approved-not yet active Age: 13 to 15 Sponsor: Other Protocol IDs: 37207, NCT01021904
3.	Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Phase: Phase IV Type: Prevention Status: Active Age: 15 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 109823, NCT01031069
4.	Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Phase: Phase IV Type: Prevention Status: Active Age: 11 to 17 Sponsor: Other Protocol IDs: GardasilMerckGomez-Lobo, NCT01101750
5.	Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Phase: Phase IV Type: Prevention Status: Approved-not yet active Age: 18 to 26 Sponsor: Other Protocol IDs: CIHR-MOP-125949, IIS #38265, NCT01824537
6.	Diindolylmethane in Treating Patients With Abnormal Cervical Cells. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Prevention Status: Active Age: Not specified Sponsor: Other Protocol IDs: CRUK-CRISP-1, ISRCTN47437431, EU-20717, NCT00462813
7.	Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study Phase: Phase III Type: Prevention Status: Active Age: 26 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113621, NCT01190189
8.	The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study Phase: Phase III Type: Prevention Status: Active Age: 26 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113618, NCT01249365
9.	Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study Phase: Phase III Type: Prevention Status: Active Age: 26 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 114379, NCT01418937
10.	Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine in Healthy Female Children Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 4 to 6 and 15 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 115887, 2011-005604-15, NCT01627561
11.	Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5) Phase: Phase III Type: Prevention Status: Active Age: 16 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: V503-003, 2012-001375-36, NCT01651949
12.	Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent(Type 16/18 )Vaccine Phase: Phase III Type: Prevention Status: Active Age: 18 to 45 Sponsor: Other Protocol IDs: HPV-PRO-003, NCT01735006
13.	Folic Acid Clinical Trial for the Prevention of Cervical Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 19 and over Sponsor: NCI, Other Protocol IDs: CDR0000579360, UAB-F060511015, UAB-IRB0000196, F060511015, NCT00703196
14.	Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 to 25 Sponsor: Other Protocol IDs: HPV-PRO-002, NCT01356823
15.	Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia Phase: Phase I Type: Biomarker/Laboratory analysis, Prevention, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: JHOC-J0656, J0656, NA_00002176, NCT00788164
16.	A Phase I Clinical Trial of an HPV Therapeutic Vaccine Phase: Phase I Type: Prevention Status: Active Age: 18 to 50 Sponsor: NCI, Other Protocol IDs: 130662, R01CA143130, NCT01653249
17.	Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 Phase: No phase specified Type: Prevention, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000460044, UCSF-03421, UCSF-H7810-25693-01, UCSF-H7810-25693-02A, NCT00278434
18.	Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention Phase: No phase specified Type: Health services research, Prevention Status: Active Age: 9 to 13 Sponsor: Other Protocol IDs: 36448, NCT01096134
19.	A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study Phase: No phase specified Type: Health services research, Prevention, Screening Status: Active Age: 18 to 26 Sponsor: Other Protocol IDs: 33249, NCT01133509
20.	Trial to Evaluate Single- and Double-freeze Cryotherapy in the Prevention of Cervical Neoplasia Phase: No phase specified Type: Prevention, Treatment Status: Active Age: 25 to 64 Sponsor: Other Protocol IDs: 649, NCT01145781
21.	Prevent Exposure to Tobacco Smoke at Home [Gesunde Atemluft zu Hause] Phase: No phase specified Type: Behavioral study, Prevention Status: Approved-not yet active Age: 3 and under Sponsor: Other Protocol IDs: Krebshilfe-107539, DM8-IESO02, NCT00647413
22.	An Intervention Study To Improve HPV Immunization in Haitian and African American Girls Phase: No phase specified Type: Behavioral study, Educational/Counseling/Training, Prevention Status: Active Age: 11 to 15 Sponsor: Other Protocol IDs: H26306, NCT01254669
23.	The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in Chronic Kidney Disease (CKD) Patients Phase: No phase specified Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 to 26 Sponsor: Other Protocol IDs: 2011/02_Medicine, NCT01298869
24.	Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka Phase: No phase specified Type: Prevention Status: Approved-not yet active Age: 10 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113763, NCT01551537